#primary progressive multiple sclerosis

[queerlyloud]

Yall, medical trauma is wild as hell. My PCP asked me the basic MS diagnostic questions at our appointment on Thursday after I told her about the pain in my spine that woke me up out of a sleep induced by tizanidine AND meclizine. Like I should have been dead to the world for 8-10 hours, but the pain was so bad it woke me from that heavy a sleep and was so intense that I was in too much shock to move for more than 2 minutes after I woke up. Literally paralyzed by the pain.

Anyway, I told her about that and about how even though I told the neurologist I was referred to that, he only had an MRI done on my head, neck, and upper vertebrae , with absolutely none done of my middle or lower spine, despite those being my primary pain centers. So my PCP immediately booked me for x-rays of my spine so that a full spine MRI would be approved by my shitty work insurance.

I have every single symptom of PPMS, all I need is for an MRI to catch lesions on my spine so they can do the tap and identify the inflammation in my spine that shows up in every single blood work I've had done in the past 5 years.

I might finally get my diagnosis.

But instead of being excited and happy, my brain is instead choosing to have me pre-experience the depression I will feel if they don't spot any lesions on the MRI.

Fml 🙃

[full-metal-femme]

I'd seen an article about this earlier in the year and while I dont think this is an update, it's always worth sharing, especially since it looks like they're looking for trial participants 🤘🏻

My dad has MS, i'm about the age he was diagnosed now (early 30's), and the thought of a cure in our lifetimes? Fucking mind blowing. He has been slowly robbed of his physical ability over 30 years and now it is affecting his mental ability too so I don't know if 2035 is something he'll live to see but considering when he got it (early 90's), the treatment was "hope for the best and treat symptoms", this is just... I don't even have words for how incredible that is.

I often think about how I would take the news of a diagnosis like that. He was early 30's, had a 2 year old kid and a brand new baby (me), a mortgage, etc. Life just beginning you could say. Then to be given basically a death sentence, prolonged over however long the rest of your life might be - mercifully short and less suffering, or longer and painful but you get to be with your family. I don't know how he managed.

Anyway, rambling. This is good news and an exciting thing to look forward to!

[caregiversherry]

Josh (my husband) started using a walker recently. Before that he was using a cane. Our 10 year anniversary was this past weekend and we had pictures taken in NYC in front of a horse and carriage. Josh posted a picture with his walker in it for the first time on Facebook and an acquaintance of his commented something that needs to be discussed. He said that Josh needs to stop selling himself short by using assistance to walk and that he’s stronger than that. This is not only ignorant but hurtful. No one knows what someone else is going through and not everyone with MS has the same level of symptoms. It is not safe for him personally to walk without assistance, such as a cane or walker at this point due to falls and extremely poor balance. I could definitely go on forever about MS awareness but in a nutshell, no two people are alike. Don’t tell someone who is trying to better their quality of life to stop selling themself short. In fact, maybe ask why they’re using it instead if you (clearly) don’t know.

[chronicallyuniconic]

that's the thing about primary progressive multiple sclerosis

it doesn't get better

[twwpress]

Weekly Press Briefing #93: March 31st - April 6th

Welcome back to the Weekly Press Briefing, where we bring you highlights from The West Wing fandom each week, including new fics, ongoing challenges, and more! This briefing covers everything posted from March 31 - April 6, 2024. Did we miss something? Let us know; you can find our contact info at the bottom of this briefing!

Challenges/Prompts:

There are no open challenges or events on our radar this week. Do you have a challenge or event you’d like us to promote or know of one we’re missing? Be sure to get in touch with us! Contact info is at the bottom of this briefing.

This Week in Canon:

Welcome back to This Week in Canon, where we revisit moments in The West Wing that occurred on these dates during the show’s run.

Season 1, Episode 18: Six Meetings Before Lunch aired on April 5, 2000.

Season 2, Episode 18: 17 People aired on April 4, 2001.

Season 3, Episode 17: Stirred aired on April 3, 2002.

Season 4, Episode 19: Angel Maintenance aired on April 2, 2003.

Season 5, Episode 18: Access aired on March 31, 2004.

Season 6, Episode 22: 2162 Votes aired on April 6, 2005.

Photos/Videos:

Here’s what was posted from March 31 – April 6:

Allison Janney posted a still from this week’s Palm Royale episode. 

Allison Janney posted a video of herself dancing on the set of Palm Royale, along with a shout out to her hairstylist. 

Janel Moloney posted a photo of the Fortnite-themed Durr Burgers she made for her sons. 

Josh Malina posted screenshots of his wedding gift to another Josh Malina. Josh Malina posted a photo of himself impersonating Bart Simpson. 

Peter James Smith posted photos from rehearsal for his upcoming play, Nora, which previews April 21. 

Rob Lowe posted a photo of his dogs looking at the ocean. 

Donna Moss Daily: March 31 | April 1 | April 2 | April 3 | April 4 | April 5 | April 6

Daily Josh Lyman: March 31 | April 1 | April 2 | April 3 | April 4 | April 5 | April 6

No Context BWhit: March 31 | April 1 | April 2 | April 3 | April 4 | April 5 | April 6 

@twwarchive: April 1 | April 2 | April 3 | April 4 | April 6

@twwgifs: April 2

Editors’ Choice: 

Here are a few fics based on or featuring points from episodes that had airdate anniversaries this week. Be sure to share your favorites with us, too!

Four Days by TheBreakfastGenie | Rated G | Josh Lyman & Toby Ziegler (No Pairings Listed) | Complete | After the president tells Josh he has multiple sclerosis, Toby is waiting in his office. Josh and Toby talk about re-election, loyalty, and a few other things. Five Minutes and the Future by glassessay | Rated T | Josh Lyman/Donna Moss | Complete | “I don’t want to be angry about it anymore,” he says. “I’m tired, Donna. I just want my best friend back.” “Sam’s in California,” she says. “Did you not hear the capital letters? Capital B capital F Best Friend, Donna, I’m talking little matching charms on our bracelets—" “I’m tired too,” she blurts out. “It’s been a long primary.” It’s less than an hour before what’s likely the last speech of the Santos campaign, and Josh has an apology he needs to make. all I need’s a whisper in a world that only shouts by Luppiters | Rated M | Danny Concannon/C.J. Cregg | In Progress | Drabbles and ficlets inspired by requests, prompts, and just about anything, written over the years. Mostly C.J./Danny, together and apart. The Jackal, a Brief History by aronos_zitro | Rated G | Andrea Wyatt/Toby Ziegler | Complete | Have you ever wondered how The Jackal became a "thing" for CJ and the staff? Here's a brief history of how we came to have this timeless scene from "Six Meetings Before Lunch" (S01E18). Oneshot.

Fics:

Presenting your weekly roundup of fics posted in the tag for The West Wing on Archive of Our Own. 

Josh/Donna

this is the wonder (that's keeping the stars apart) by joshatella (shuuuliet) | Rated T | Josh Lyman/Donna Moss | In Progress

The Theory of Entropy by Jane_3yr3 | Rated M | Josh Lyman/Donna Moss | Complete

A Year In the Life by Proportional Response | Not Rated | Josh Lyman/Donna Moss | In Progress

CJ/Toby

In Plain Sight by JediAnnieScrambler | Rated M | C. J. Cregg/Toby Ziegler | Complete

Other Pairings/Gen Fic

Sam Seaborn is Interviewed by Hackney123 | Rated G | No Pairings Listed | Complete

Regarding Jamie: Sound and Fury by mlea7675 | Rated G | Helen Santos/Matt Santos | In Progress

Allergies by shecouldnotcomeupwithaname | Rated G | C. J. Cregg/Kate Harper | Complete

i could be your (crush crush crush) by taliamytaliae | Rated T | Josh Lyman/Sam Seaborn | Complete

EAD2021: Fight for All by hellbells (NCIS crossover) | Rated T | Anthony DiNozzo/Sam Seaborn | In Progress

We had a deal by Labda | Not Rated | Abbey Bartlet/Jed Bartlet | In Progress

Helen Visits Wisconsin by Hackney123 | Not Rated | Donna Moss/Helen Santos | Complete

THE WEEKLY PRESS BRIEFING TEAM CAN BE REACHED VIA THE FOLLOWING METHODS:

Twitter: @twwpress Email: weeklypressbriefing@gmail.com

Feel free to let us know if we missed something, if you have an event you’d like us to promote, or if you have an item that you’d like included in the next briefing!

xx, What’s next?

[scientificinquirer-blog]

DAILY DOSE: Saudi universities exposed for paying-off top scientists to steal some shine; Endangered Sumatran rhino born in captivity.

STEM CELL THERAPY FOR MS. A recent early-stage trial has shown promising results for a new stem cell therapy for multiple sclerosis (MS). In this trial, neural stem cells were injected into the brains of 15 patients with secondary progressive MS, a more advanced stage of the disease where few treatments are effective. The primary aim was to assess safety, and the results were encouraging,…

[darlingdollhousevn]

If it's not too much of a spoiler, what chronic neurological illness does Lowell have? (Unless it's already posted somewhere and I just didn't notice, in which case my bad)

The conditions he has themselves are not spoilers! Lowell's primary diagnoses are Mixed Connective Tissue Disease and Relapsing Remitting Multiple Sclerosis that is starting to progress more rapidly. He also suffers from gastroparesis, which makes it incredibly difficult for him to eat properly, a thyroid disorder, and he was just diagnosed with the beginning stages of rheumatoid arthritis at the onset of the game.

Lowell has been ill since he was a child, but he grew up in a neglectful household so he didn't recieve necessary medical care, and he both went to culinary school and now works as a commercial baker. He was essentially able to push past a lot of his symptoms to appear able bodied and has worked well past his limits for a long time, at massive detriment to his body- he's starting to feel the effects of his conditions acutely, and his ability to maintain his job and live a relatively normal life are declining rapidly.

I'm sparing the gorey details of how his conditions effect him in the two milder routes, but they will be playing a large part in the croquembouche route.

Lowell's feelings of losing control within his own body highly inform his character and his actions, and are drawn in large part by my own struggle with chronic and progressive disabilities- we don't share all of our diagnoses, but Lowell does have a few conditions that I myself suffer from.

[mommyisdownwiththesickness]

INTRODUCTIONS ARE IN ORDER

Hey there! I’m Angie and this is a blog for pretty much things I’m into and about my life and living with chronic auto-immune illnesses.

- so, what are these chronic immune issues you have then? -

I never thought you’d ask!

1. Hashimotos Disease :

- hashimotos disease is a thyroid disorder. It’s where your thyroid fluctuates between over and under active!

- the interesting thing about the thyroid is that it is the house for several of your hormones. The main hormones it hold is your body’s metabolism. It also plays a role in controlling your heart, muscle and digestive function, brain development, and bone management.

- my experience with the beginnings of my thyroid issues. In the beginning I would fall asleep at random moments, have extreme outbursts emotionally, and weigh gain.

- no cure, managed medically

2. Type 1 Diabetes :

- type 1 diabetes is very different than type 2 diabetes. T1D (Type 1 diabetes) affects your pancreas and insulin production. With T1D your pancreas produces little to no insulin on its own. T2D you either don’t produce enough insulin or you are insulin resistant.

- T1D is usually diagnosed in adolescent years as T2D is usually diagnosed in your adult years.

- I was diagnosed with T1D when I was 16 years old. As time went on and my pancreas basically gave up on producing insulin to where I had to become dependent on an insulin pump. I am basically a cyborg because I have a robotic pancreas that gives me insulin all day long to keep my blood sugars within a normal range.

- no cure, managed medically

3. Multiple Sclerosis :

- multiple sclerosis is where your immune system decides the nerves on your brain are attacking and therefore your immune system attacks the nerves on your brain breaking down the myelin coating protecting the nerves causing so many shitty symptoms.

- because the immune system is attacking the myelin, it affects your entire body because the nerve damage disrupts the communication between your brain and your body.

- there are several different levels of disability when it comes to MS (multiple sclerosis):

> CIS : Clinically Isolated Syndrome

The first episode of MS caused by inflammation and damage to the myelin. CIS doesn’t meet the requirements for an MS diagnosis

> RRMS : Relapsing-Remitting MS

It generally follows a predictable pattern where symptoms worsen and then improve. You have relapsing periods of “flare ups” and then you have a period of remission (no symptoms). Remission can last days to decade depending on MS drug management

> SPMS : Secondary Progressive MS

SPMS is the progression of RRMS. It is much more aggressive. They may have small lapses of remission but the disease and damage is noticeable and continues on worsen

> PPMS : Primary Progressive MS

A very uncommon diagnoses of MS. It affects around 10% - 15% of people after the diagnosis of SPMS. It is a slow and steady progression of MS with no remission periods.

- my experience with MS caused issues with my vision first. My left eye was blurry and lights were really bright. It was called optic neuritis due to MS. As it progressed I had trouble walking and would have to use a cam for balance reasons due to falling.

-no cure, managed medically

Oof. That’s a lot of bullshit, huh?

Luck for me I can manage my auto-immune issues with medications, physical therapy, medical devices, and chemotherapy.

If you have any questions about any of my issues, feel free to reach out!

If you’re just like me, I would love to connect!

Now that you know more about me, I would love to know more about you! Especially if you made it this far in this long ass post!

[zhaoneurology]

What Is The First-Line Treatment For Multiple Sclerosis?

The first-line treatment for multiple sclerosis (MS) aims to modify the course of the disease, manage symptoms, and reduce the frequency and severity of relapses. MS is a chronic autoimmune disease that affects the central nervous system (CNS), leading to the deterioration or permanent damage of nerve fibers and their protective covering, the myelin sheath. Early intervention with first-line treatments is critical in slowing the progression of the disease and improving the quality of life for patients.

Disease-Modifying Therapies (DMTs)

Disease-modifying therapies (DMTs) are the cornerstone of first-line treatment for MS. These medications are designed to modify the course of the disease by targeting the underlying immune system dysfunction that causes the immune system to attack the CNS. DMTs are primarily used in relapsing forms of MS, which include relapsing-remitting MS (RRMS), where patients experience episodes of worsening symptoms (relapses) followed by periods of remission.

Several DMTs are approved as first-line treatments for RRMS, including:

Injectable DMTs:

Interferon beta (IFNβ): This is one of the most commonly prescribed first-line treatments for MS. It works by modulating the immune response and reducing inflammation in the CNS. Common forms include IFNβ-1a and IFNβ-1b. It has been shown to reduce the frequency of relapses and delay disease progression.

Glatiramer acetate: Another popular injectable DMT, glatiramer acetate works by modifying the immune response to protect nerve cells from attack. It also helps reduce relapse rates and the number of new lesions in the brain.

Oral DMTs:

Fingolimod: This oral medication works by trapping immune cells in the lymph nodes, preventing them from attacking the CNS. Fingolimod has been shown to reduce relapse rates and new lesion formation.

Dimethyl fumarate: This drug has anti-inflammatory effects and may protect nerve cells from damage. It has been demonstrated to reduce relapse rates and delay progression in MS patients.

Monoclonal Antibodies:

Ocrelizumab is a monoclonal antibody that targets and depletes certain B cells, a type of immune cell that plays a role in MS. It is used for both relapsing and primary progressive forms of MS, showing promise in improving outcomes in these patients.

Symptom Management

While DMTs address the underlying disease progression, managing MS symptoms is equally important in improving patients' quality of life. Symptoms such as fatigue, spasticity, pain, and bladder dysfunction are common in MS and may require additional treatments, such as physical therapy, medications for spasticity (e.g., baclofen or tizanidine), and pain management strategies.

In summary, the first-line treatment for MS involves using disease-modifying therapies, including injectable, oral, and monoclonal antibody medications, to reduce relapses, manage inflammation, and slow disease progression. Managing symptoms is also crucial to improving daily functioning and overall well-being for MS patients. Early diagnosis and treatment are essential for better long-term outcomes in individuals living with MS.

[health-views-updates]

Global Multiple Sclerosis (MS) Market: Growth, Trends, and Forecast (2024-2032)

The global Multiple Sclerosis Market Revenue, which was valued at USD 21.5 billion in 2023, is projected to grow to USD 39.20 billion by 2031. This growth is expected to occur at a compound annual growth rate (CAGR) of 7.8% over the forecast period from 2024 to 2031. The expansion of the MS market reflects the increasing demand for advanced treatment options, ongoing research and development in the field, and the growing prevalence of the disease worldwide.

Market Dynamics and Growth Drivers

Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, leading to a wide range of neurological symptoms. The market for MS treatments includes a variety of drug therapies, including disease-modifying therapies (DMTs), symptom management drugs, and advanced biologics. The growing focus on improving the quality of life for MS patients, along with the need for effective disease management, is a significant driver of the market.

One of the primary factors contributing to the growth of the MS market is the increase in funding for research and development. Pharmaceutical companies are investing heavily in the development of new therapies that offer better efficacy, fewer side effects, and improved administration methods. Additionally, the availability of novel biologics and the introduction of advanced drug delivery systems are enhancing treatment outcomes, leading to an increase in the adoption of MS therapies.

Get Free Smaple Report@ https://www.snsinsider.com/sample-request/2706

Key Market Trends

The introduction of oral therapies has been a game-changer for the MS market. Traditionally, MS treatments involved injectable therapies, which were often associated with discomfort and inconvenience. The availability of oral DMTs has significantly improved patient adherence and satisfaction, thus driving market growth.

Advancements in biotechnology have paved the way for the development of monoclonal antibodies, which are used to target specific mechanisms of the disease. These biologics are showing promise in reducing the frequency of relapses and slowing disease progression, offering new hope for patients who have not responded to conventional treatments.

The global MS market is also benefiting from government initiatives and support programs that aim to improve access to treatment. Awareness campaigns and funding for MS research are increasing, particularly in developed regions, leading to the availability of more treatment options and diagnostic tools.

Regional Insights

North America held the largest share of the Multiple Sclerosis Market in 2023, driven by the presence of a well-developed healthcare infrastructure, high healthcare expenditure, and the availability of advanced treatment options. The United States, in particular, is at the forefront of MS research and has seen the approval of several innovative therapies in recent years.

Europe is another significant market for MS treatments, with countries such as Germany, France, and the United Kingdom leading the way. The region’s focus on improving healthcare systems and the presence of key pharmaceutical companies are factors contributing to market growth. Meanwhile, the Asia-Pacific region is expected to exhibit the highest growth rate during the forecast period, owing to increasing healthcare awareness, rising prevalence of MS, and improvements in healthcare infrastructure.

Key Players in the Market

The Multiple Sclerosis Market is characterized by the presence of several key players who are actively engaged in research, development, and commercialization of MS therapies. Leading companies include Biogen, Novartis AG, Merck KGaA, Roche, and Sanofi. These companies are focusing on strategic collaborations, mergers and acquisitions, and the development of novel therapies to expand their market presence and cater to the growing demand for effective MS treatment solutions.

Conclusion

The global Multiple Sclerosis Market is set to experience significant growth over the next decade, driven by advances in treatment options, increased investment in research and development, and a growing emphasis on patient care and disease management. As the prevalence of MS continues to rise, the demand for innovative therapies will likely increase, offering lucrative opportunities for pharmaceutical companies and healthcare providers.

[medphy20]

Understanding Multiple Sclerosis: The Role of Exercise in Managing the Condition

Multiple sclerosis (MS) is a chronic disease that affects the central nervous system, disrupting communication between the brain and the body. This complex condition can lead to a range of physical and cognitive symptoms that significantly impact the daily lives of those affected. As we explore MS, it’s essential to highlight the critical role that exercise plays in its management.

What is Multiple Sclerosis?

MS is an autoimmune disorder where the immune system mistakenly attacks the myelin sheath — the protective covering of nerve fibres. This can result in symptoms such as fatigue, muscle weakness, balance issues, and cognitive changes. The National Multiple Sclerosis Society (2023) provides an overview of the various types of MS, including Relapsing-Remitting MS and Primary Progressive MS, each presenting unique challenges for individuals.

Types of Multiple Sclerosis

There are several forms of MS, including:

Relapsing-Remitting MS (RRMS): Characterized by episodes of symptom flare-ups followed by recovery.

Secondary Progressive MS (SPMS): Initially starts as RRMS but progresses to a steady decline.

Primary Progressive MS (PPMS): Involves gradual worsening from the onset without distinct relapses.

Progressive-Relapsing MS (PRMS): A rare type with continuous progression and occasional relapses.

The Importance of Exercise for Individuals with MS

Exercise is a cornerstone in managing MS and can have profound benefits that extend well beyond physical fitness. Engaging in regular physical activity offers a range of advantages for those living with MS.

1. Enhancing Physical Function Regular exercise can improve mobility, strength, and overall physical function. Research indicates that individuals with MS who engage in exercise show significant improvements in muscle strength and endurance (Kalb et al., 2020). This can lead to better performance in daily activities and an enhanced quality of life.

2. Reducing Fatigue Fatigue is one of the most debilitating symptoms of MS. Interestingly, studies have shown that regular physical activity can actually help reduce fatigue levels. A systematic review by Pilutti et al. (2013) found that exercise training is associated with significant reductions in fatigue among individuals with MS, thereby improving their overall well-being.

3. Improving Balance and Coordination Individuals with MS often experience balance issues, increasing the risk of falls. Exercise programs that include balance training can enhance stability and coordination. According to Motl and Pilutti (2012), tailored exercise interventions can lead to improvements in balance, thus reducing fall risk.

4. Boosting Mental Health While the primary focus is on physical benefits, it’s worth noting that exercise can also positively affect mental health. Engaging in regular physical activity can reduce symptoms of anxiety and depression, common in individuals with MS (Latimer-Cheung et al., 2013). The sense of achievement from sticking to an exercise routine can foster a more positive outlook.

5. Fostering a Supportive Community Group exercise classes can provide a supportive environment, allowing individuals with MS to connect with others facing similar challenges. This sense of community can be incredibly motivating and beneficial for mental well-being.

6. Promoting Overall Health Staying active is essential for overall health. Regular exercise reduces the risk of additional chronic diseases, such as obesity and cardiovascular disease, which can further complicate MS management (Moore et al., 2016).

Tailoring Exercise Programs

It’s vital for individuals with MS to work with healthcare professionals, like exercise physiologists or physiotherapists, to create customized exercise plans. These programs should focus on:

Safety: Ensuring that exercises are safe and suitable for each individual’s condition.

Adaptability: Modifying routines based on daily energy levels and symptoms.

Variety: Incorporating different types of exercise — strength training, aerobic activities, and flexibility exercises — to keep things engaging.

Conclusion

Understanding multiple sclerosis and recognizing the importance of exercise empowers individuals to take charge of their health. Regular physical activity can enhance physical function, manage symptoms, and improve overall quality of life for those with MS.

If you or someone you know is navigating the challenges of MS, consider signing up for personalized support at MedPhys Rehabilitation. Our experienced team is dedicated to helping you create a tailored exercise plan that meets your unique needs. Remember, every step counts on the path to a healthier, more active future.

[neurodiscoveryai]

6 Debilitating Neurological Disorders and the Search for Potential Cures

This article discusses six neurological disorders which presently have no definite cure. Also, how AI is being used to find new treatments for these diseases. These disorders are Multiple Sclerosis (MS), Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), Migraine and Autism Spectrum Disorders (ASD).

Multiple sclerosis (MS) is a neurological disorder which affects the central nervous system (CNS). For a patient suffering from MS, their immune system attacks myelin (protective cover of nerve fibers) by mistake. It causes cognitive impairment, paralysis, numbness, blurred vision, coordination problems and fatigue. There is a serious need for new drug discovery approaches as there is no complete cure available. NeuroDiscovery AI is using artificial intelligence to make advances in helping to find cures for MS.

The company uses real world data (RWD) like EHRs (electronic health records) and treatment outcomes to analyze disease progression and treatment efficiency. Their AI platform analyzes huge medical datasets to help in patient recruitment and designing effective clinical trials. This assists biotech researchers and pharmaceutical companies to identify potential drug candidates. The platform collaborates with neurological care providers, academic institutions and life sciences companies to provide large patient datasets. It is leading to a complete transformation of the MS drug discovery process as artificial intelligence is continuously evolving.

Parkinson's disease (PD) is a progressive CNS disorder which largely affects movement. This occurs with the degeneration of nerve cells in substantia nigra (a part of the brain). These nerve cells create dopamine which is a neurotransmitter crucial for coordinated and smooth muscle movement. Patients go through symptoms like balance issues, slowness of movement, stiffness, tremors, sleep disturbances, cognitive decline, changes in speech and depression. 

PD is supposed to be caused by trauma, environmental and genetic factors. The treatments for PD are limited to managing symptoms and improving the quality of life as there is no cure available for PD. NeuroDiscovery AI is on a mission to help in finding cures for PD with its extensive patient data and use of its AI platform.

Alzheimer’s disease (AD) is a neurodegenerative disease which impacts behavior, thinking and memory. AD is the most prevalent reason for dementia. AD starts with moderate memory loss which becomes worse gradually. This leads to cognitive impairment and decreases the patient's ability in carrying out day-to-day activities.

AD begins with symptoms like difficulties in learning new things, remembering recent events, confusion and memory loss. With its progression, patients experience mood swings, impaired judgment, trouble in speaking and disorientation. The patient loses the ability for basic communication, daily tasks and recognizing close ones. AD is supposed to be caused by lifestyle, environmental, genetic and age factors. At present, treatments for AD focus on managing symptoms, improving quality of life for patients and slowing disease progression. NeuroDiscovery AI envisions a world where AD can be stopped and even reversed.

Frontotemporal dementia (FTD) is a category of CNS disorders which affects the frontal and temporal lobes in the brain. This leads to changes in motor skills, personality and overall behavior in patients. There are three primary types of FTD, Behavioral variant FTD (bvFTD), Primary progressive aphasia (PPA) and FTD with movement disorders.

bvFTD is the degeneration in the frontal lobe which results in personality changes. PPA mainly affects a patient's language skills. PPA patients lose fluency in speaking, have problems in sentence forming and have difficulties in finding the correct words. FTD with movement disorders have motor symptoms like movement issues, tremors and stiffness which are similar to symptoms found in ALS (amyotrophic lateral sclerosis) and PD. We at NDAI are assisting life sciences companies in neuro research to find a cure for FTD.

Migraine is the most common CNS disorder which can be described by repeated headaches of different intensities. It impacts a patient's quality of life and daily activities. The other symptoms which follow migraine are auras (visual disturbances), nausea (urge to vomit), phonophobia (sensitivity to sound) and photophobia (sensitivity to light). Generally, a migraine attack advances in four phases, Prodrome, Aura, Headache and Postdrome. All patients may not experience all four phases.

Prodrome is the first phase occurring hours/days before headache which has symptoms like neck stiffness, mood swings, fatigue and food cravings. Aura has symptoms like flashing lights, blurred vision, tingling sensations and blind spots. Aura usually lasts for less than an hour. The headache phase has intense pain mostly on one side of the head which lasts between 4 hours to 3 days. This phase is also followed by symptoms like sensitivity to sound/light, nausea and vomiting. Postdrome is the last phase which lasts up to 2 days. The symptoms include fatigue, weakness, confusion and exhaustion. NDAI is working towards finding innovative cures for Migraine.

Autism Spectrum Disorder (ASD) is a neurological condition which impacts social interaction, behavior, communication ability, forming relationships and maintaining eye contact. Most often, ASD occurs by the early age of 2-3. ASD is believed to be caused by a combination of environmental and genetic factors. People with mild ASD symptoms lead independent lives. While others with major symptoms need support in daily tasks.

ASD is usually followed by symptoms like sensitivities to sound and light. This affects a person's daily life in a significant way. ASD treatment includes medical treatment, nutritional therapy, social skills training, school based therapies, occupational therapy, sensory integration therapy, behavioral therapy and cognitive therapy.

NeuroDiscovery AI is partnering with top healthcare providers, educational institutions, patient advocacy groups and life sciences companies to transform neurology with AI driven insights.

[stevenwilliam12]

The Future of HER2-Positive Treatment: Roche's Vision and Pipeline

As a pioneer in the oncology field, Roche is dedicated to transforming the landscape of HER2-positive breast cancer treatment. With a commitment to innovation and personalized medicine, Roche’s vision for the future centers on advancing therapies that not only improve survival rates but also enhance the overall quality of life for patients.

Innovative Therapies in Development

Roche’s pipeline for HER2-positive treatments reflects its ongoing commitment to research and development. Currently, several promising therapies are being investigated to provide new options for patients, especially those who may not respond to existing treatments. Key areas of focus include:

Next-Generation Antibody-Drug Conjugates (ADCs): Building on the success of Kadcyla, Roche is developing next-generation ADCs that aim to deliver more effective and targeted therapy with reduced side effects. These novel agents utilize advanced technology to enhance the potency of chemotherapy while minimizing exposure to healthy cells.

Combination Therapies: Roche is exploring innovative combinations of existing treatments to enhance efficacy. By pairing HER2-targeted therapies with immunotherapy and other agents, Roche aims to overcome resistance mechanisms and improve outcomes for patients with advanced disease.

Biomarker-Driven Approaches: Roche is focused on leveraging biomarkers to identify patients who are most likely to benefit from specific therapies. This precision medicine approach allows for tailored treatment plans, optimizing therapeutic efficacy and minimizing unnecessary side effects.

Clinical Trials and Collaborations

Roche is actively conducting clinical trials to evaluate the safety and efficacy of its emerging therapies. Collaborations with academic institutions, research organizations, and other industry leaders further bolster Roche’s ability to advance HER2-positive treatment options. These partnerships are crucial for accelerating research, sharing insights, and fostering innovation within the oncology community.

Commitment to Patient Support

Recognizing that treatment extends beyond medication, Roche is committed to comprehensive patient support. The company provides educational resources, access to clinical trials, and supportive care initiatives to empower patients and their families. Roche’s dedication to fostering a supportive environment is integral to enhancing the overall patient experience.

A Vision for the Future

Roche envisions a future where HER2-positive breast cancer can be managed more effectively, with a focus on personalized, targeted therapies that maximize patient outcomes. The company’s investment in research and development reflects its commitment to pioneering new treatments and improving the standard of care for patients.

Conclusion

As Roche continues to innovate and expand its pipeline for HER2-positive breast cancer treatments, the future looks promising. With a strong focus on advanced therapies, personalized medicine, and patient support, Roche is poised to lead the way in transforming the treatment landscape and offering new hope to patients battling this challenging disease.

Latest ReportsHearing Implants Market | Hemophilia B Market | Hepatitis B Virus Market | Hpv-induced Cancers Market | Image Guided Surgery Devices Market | Intrahepatic Cholangiocarcinoma Market | Juvenile Rheumatoid Arthritis Market | Menorrhalgia Market | Ncfb Market | Nmibc Market | Non-st Segment Elevation Acute Coronary Syndromes Market | Nonmuscle Invasive Bladder Cancer Market | Oral Mucositis Om Market | Osteosarcoma Market | Palmar Hyperhidrosis Market | Pd-1 & Pdl1 Market | Primary Progressive Multiple Sclerosis Ppms Market | Progressive Familial Intrahepatic Cholestasis Market | Prosthetic Joint Infection Market | Radiation Toxicity Market | Refractory Chronic Cough Market | Scleroderma Market | Small Fiber Neuropathy Market | Vascular Access Devices Market | Walking Impairment In Multiple Sclerosis Market

[harshnews]

Neurological Biomarkers Market Size, Share, Trends, Opportunities, Key Drivers and Growth Prospectus

"Neurological Biomarkers Market – Industry Trends and Forecast to 2030

Global Neurological Biomarkers Market, By Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson's Disease, Schizophrenia, Huntington's Disease, Alzheimer's Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical and Biotechnology Companies, Research Organizations) – Industry Trends and Forecast to 2030.

Access Full 350 Pages PDF Report @

**Segments**

- Based on product type, the neurological biomarkers market is segmented into genomics, proteomics, metabolomics, imaging, and others. Genomics segment is expected to witness significant growth due to the increasing focus on personalized medicine and genetic biomarker discoveries for various neurological disorders. - On the basis of indication, the market is divided into Alzheimer's disease, Parkinson's disease, multiple sclerosis, autism spectrum disorder, schizophrenia, bipolar disorder, and others. Alzheimer's disease segment holds a major share as it is a leading cause of dementia worldwide, resulting in a high demand for effective biomarkers for early diagnosis and monitoring of disease progression. - By end-user, the market is categorized into hospitals, diagnostic labs, research laboratories, and others. Hospitals segment dominates the market owing to the extensive use of neurological biomarkers for patient diagnosis and treatment within healthcare settings.

**Market Players**

- Thermo Fisher Scientific Inc.: Thermo Fisher Scientific is a key player in the neurological biomarkers market, offering a wide range of products and services for biomarker research and development. The company's strong focus on innovation and strategic collaborations has positioned it as a leading supplier in the market. - QIAGEN: QIAGEN is a prominent player known for its advanced solutions in molecular diagnostics, including biomarker testing. With a diverse portfolio of products catering to neurological disorders, QIAGEN plays a crucial role in advancing precision medicine and personalized healthcare. - Myriad Genetics, Inc.: Myriad Genetics specializes in molecular diagnostics and personalized medicine, with a focus on genetic biomarkers for neurological conditions. The company's expertise in genetic testing and biomarker identification has established it as a reliable partner for healthcare providers and researchers in the field.

The global neurological biomarkers market is witnessing rapid growth, driven by increasing research activities, rising prevalence of neurological disorders, and advancements in biomarker technologies. Key players are actively engaged in developing innovative solutions to address the unmet needs in neurological diagnostics and treatment. WithThe neurological biomarkers market is experiencing significant growth and transformation, propelled by several key factors influencing the market landscape. One of the primary drivers of this market expansion is the escalating research endeavors aimed at understanding the complex nature of neurological disorders. The exploration of genomics, proteomics, metabolomics, imaging, and other cutting-edge technologies has enabled a deeper comprehension of the underlying mechanisms of various neurological conditions. This increased understanding has paved the way for the development of novel biomarkers that can aid in early diagnosis, disease monitoring, and personalized treatment strategies. The emphasis on personalized medicine, especially in the genomics segment, has fueled the demand for genetic biomarker discoveries, offering a more tailored and effective approach towards managing neurological disorders.

Another crucial aspect shaping the market dynamics is the prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, autism spectrum disorder, schizophrenia, and bipolar disorder. Amongst these indications, Alzheimer's disease stands out as a major contributor to the market share due to its status as a leading cause of dementia globally. The urgent need for reliable biomarkers for the early identification and monitoring of Alzheimer's disease progression has underscored the importance of innovative diagnostic tools and technologies within the neurological biomarkers market. The increasing incidence of these neurological disorders has necessitated a concerted effort from market players to develop robust biomarker solutions that can enhance disease management and patient outcomes.

In terms of end-users, hospitals have emerged as the dominant segment within the neurological biomarkers market. The widespread utilization of neurological biomarkers in hospitals for patient diagnosis and treatment underscores the essential role played by these institutions in driving market growth. Diagnostic labs and research laboratories also play a significant role in advancing biomarker research and development, contributing to the overall expansion of the market ecosystem. Collaborations between healthcare providers, research institutions, and industry players have further facilitated the translation of biomarker discoveries from the lab to clinical practice, fostering a more integrated approach towards neurological disease management.

Key market players such as Thermo Fisher Scientific Inc.,**Segments**

- Based on product type, the neurological biomarkers market is segmented into genomics, proteomics, metabolomics, imaging, and others. The genomics segment is expected to witness significant growth due to the increasing focus on personalized medicine and genetic biomarker discoveries for various neurological disorders. - On the basis of indication, the market is divided into Alzheimer's disease, Parkinson's disease, multiple sclerosis, autism spectrum disorder, schizophrenia, bipolar disorder, and others. Alzheimer's disease segment holds a major share as it is a leading cause of dementia worldwide, resulting in a high demand for effective biomarkers for early diagnosis and monitoring of disease progression. - By end-user, the market is categorized into hospitals, diagnostic labs, research laboratories, and others. Hospitals segment dominates the market owing to the extensive use of neurological biomarkers for patient diagnosis and treatment within healthcare settings.

**Market Players**

- Thermo Fisher Scientific Inc.: Thermo Fisher Scientific is a key player in the neurological biomarkers market, offering a wide range of products and services for biomarker research and development. The company's strong focus on innovation and strategic collaborations has positioned it as a leading supplier in the market. - QIAGEN: QIAGEN is a prominent player known for its advanced solutions in molecular diagnostics, including biomarker testing. With a diverse portfolio of products catering to neurological disorders, QIAGEN plays a crucial role in advancing precision medicine and personalized healthcare. - Myriad Genetics, Inc.:

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Neurological Biomarkers Market Landscape

Part 04: Global Neurological Biomarkers Market Sizing

Part 05: Global Neurological Biomarkers Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Neurological Biomarkers Key Benefits over Global Competitors:

The report provides a qualitative and quantitative analysis of the Neurological Biomarkers Market trends, forecasts, and market size to determine new opportunities.

Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Top impacting factors & major investment pockets are highlighted in the research.

The major countries in each region are analyzed and their revenue contribution is mentioned.

The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients

Browse Trending Reports:

Mhealth Solutions Market Telecom Cloud Billing Market Industrial Cooking Fire Protection Systems Market Food Manufacturing Market Natural Surfactant Market Industrial Networking Solutions Market Facility Management Market Cathode Materials Market High Purity Gases Market Cassava Starch Market Embedded Connectivity Solutions Market Central Fill Pharmacy Automation Market Rfid In Healthcare Market Virtual Pipeline Systems Market Fiberoptic Phototherapy Equipment Market Suture Passer Market Baby Apparel Market Peanut Allergy Treatment Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[fyzical-lawrenceville-sugarloaf]

FYZICAL Balance Therapy in Lawrenceville, GA: Enhancing Mobility and Reducing Fall Risk

In Lawrenceville, GA, FYZICAL Balance Therapy stands as a crucial healthcare service designed to enhance mobility, prevent falls, and improve the overall quality of life for individuals dealing with balance issues. This innovative therapy focuses on addressing various conditions that affect balance, from vestibular disorders to age-related balance impairments. With specialized care tailored to each patient, FYZICAL has become a leading provider for those seeking comprehensive solutions to balance and mobility challenges.

What is Balance Therapy?

Balance therapy is a specialized branch of physical therapy that aims to address difficulties related to stability, coordination, and mobility. Many individuals, particularly seniors, experience balance impairments due to aging, injuries, or underlying medical conditions such as vestibular disorders, neurological issues, or musculoskeletal weaknesses. These impairments can significantly increase the risk of falls, which are a major cause of injury and disability in older adults.

FYZICAL Balance Therapy employs a variety of techniques and state-of-the-art technology to evaluate and treat these balance impairments. Whether patients suffer from dizziness, vertigo, or general instability, FYZICAL's programs are designed to improve their confidence and ability to move safely.

Key Benefits of FYZICAL Balance Therapy

Fall Prevention: One of the primary goals of FYZICAL Balance Therapy is to reduce the risk of falls. Falls are a leading cause of serious injury among older adults, often leading to fractures and long recovery periods. The therapy uses exercises to strengthen muscles, improve coordination, and teach safer movement strategies.

Vestibular Rehabilitation: For patients dealing with dizziness and vertigo, vestibular rehabilitation plays a significant role. FYZICAL therapists assess the inner ear and vestibular system, creating personalized exercises to help patients regain their sense of balance and alleviate symptoms of dizziness.

Improved Mobility: The program helps patients improve their overall mobility, enabling them to carry out everyday tasks with greater ease and independence. By targeting muscles in the legs, core, and lower back, balance therapy enhances strength and endurance.

Customized Treatment Plans: FYZICAL develops personalized treatment plans that consider each patient's specific needs. This individualized approach ensures that therapy is both effective and engaging, whether a patient requires assistance with balance due to age-related issues, a neurological disorder, or an orthopedic condition.

State-of-the-Art Technology: FYZICAL clinics are equipped with advanced technology designed to assess and treat balance disorders. This includes balance tracking systems and fall prevention equipment that can provide real-time feedback to both patients and therapists, ensuring continuous progress and safety during therapy sessions.

Conditions Treated with Balance Therapy

FYZICAL Balance Therapy in Lawrenceville caters to patients with a variety of conditions, including:

Vestibular Disorders: Issues with the inner ear can lead to symptoms like vertigo, dizziness, and imbalance. Vestibular rehabilitation is designed to retrain the brain to manage these symptoms, improving balance and reducing discomfort.

Post-Stroke Rehabilitation: Balance and coordination are often compromised following a stroke. FYZICAL’s balance therapy helps stroke survivors regain their ability to walk and move independently, improving their overall quality of life.

Neurological Conditions: Conditions such as Parkinson’s disease or multiple sclerosis can cause balance difficulties. FYZICAL’s balance therapy can improve motor function and reduce the risk of falls, helping patients maintain mobility.

Post-Surgical Rehabilitation: After certain surgeries, especially orthopedic surgeries involving the hips, knees, or spine, patients may struggle with balance. Balance therapy assists in regaining strength and stability, facilitating a quicker and safer recovery.

The FYZICAL Difference

FYZICAL's balance therapy is unique due to its holistic and individualized approach. Unlike traditional physical therapy clinics, FYZICAL focuses not only on treating the physical symptoms but also on educating patients to prevent future issues. Their team of highly trained therapists is dedicated to helping patients regain control over their balance, reduce their fear of falling, and improve their overall confidence in daily movements.

Additionally, FYZICAL Lawrenceville takes pride in creating a welcoming and supportive environment where patients feel comfortable and motivated to achieve their goals. Their hands-on approach ensures that every patient receives the attention they need to succeed in their balance therapy program.

Conclusion

For residents in Lawrenceville, GA, dealing with balance issues, FYZICAL Balance Therapy offers a lifeline to better mobility and independence. With its specialized programs, advanced technology, and expert therapists, FYZICAL is at the forefront of balance therapy and fall prevention. By focusing on personalized care and proactive treatment, FYZICAL is helping countless individuals regain their stability, confidence, and quality of life.

[medtravellers87]

Stem Cell Therapy for Multiple Sclerosis: A Promising Frontier in Treatment

Multiple sclerosis (MS) is a challenging autoimmune disorder that affects millions worldwide. As researchers continue to seek more effective treatments, stem cell therapy has emerged as a promising avenue for managing and potentially modifying the course of this disease. This blog post explores the current landscape of stem cell therapy for MS, its potential benefits, challenges, and what patients should know.

Understanding Stem Cell Therapy for MS

Stem cell therapy for MS aims to achieve three primary goals:

Reduce inflammation and demyelination

Repair or replace damaged nerve tissue

Promote neuroregeneration

These objectives address the core issues of MS, potentially offering hope for improved outcomes and quality of life for patients.

Types of Stem Cells Used

Researchers are exploring several types of stem cells in MS treatment:

Mesenchymal Stem Cells (MSCs): Derived from bone marrow, fat tissue, or umbilical cord tissue.

Hematopoietic Stem Cells (HSCs): Obtained from bone marrow or peripheral blood.

Neural Stem Cells (NSCs): Sourced from fetal brain tissue or induced pluripotent stem cells (iPSCs).

Each type of stem cell offers unique properties and potential benefits in treating MS.

Potential Benefits

Stem cell therapy shows promise in several areas:

Reduced relapse rates

Improved cognitive function

Enhanced motor function

Decreased fatigue

Potential for disease modification

These benefits could significantly improve the lives of MS patients, offering hope for better management of symptoms and potentially slowing disease progression.

Current Research and Trials

The scientific community is actively investigating stem cell therapies for MS through various approaches:

Autologous Hematopoietic Stem Cell Transplantation (AHSCT)

Mesenchymal Stem Cell Transplantation (MSCT)

Neural Stem Cell Transplantation (NSCT)

These trials aim to establish the safety and efficacy of different stem cell therapies in treating MS.

Challenges and Limitations

Despite its promise, stem cell therapy for MS faces several challenges:

Variability in stem cell sources and protocols

Limited understanding of MS pathology

Potential risks (infection, graft-versus-host disease)

High cost and limited accessibility

Researchers and clinicians are working to address these challenges to make stem cell therapy a more viable option for MS patients.

Clinics and Centers Offering Stem Cell Therapy for MS

Several institutions worldwide are at the forefront of stem cell therapy for MS:

Cleveland Clinic (USA)

University of California, San Francisco (USA)

Medtravellers Stem Cell Therapy (India)

San Raffaele Hospital (Italy)

Apollo Hospitals (India)

It’s important to note that insurance coverage for these treatments is limited, and most are still considered experimental.

Before Considering Stem Cell Therapy

If you’re an MS patient considering stem cell therapy, it’s crucial to:

Consult a neurologist or MS specialist

Research reputable clinics and trials

Understand potential risks and benefits

Ensure informed consent

Conclusion

Stem cell therapy represents a promising frontier in the treatment of multiple sclerosis. While challenges remain, ongoing research and clinical trials offer hope for improved outcomes and quality of life for MS patients. As with any emerging treatment, it’s essential for patients to stay informed, consult with medical professionals, and carefully consider their options.

Source Link:- https://www.medtravellers.com/blog/stem-cell-therapy-for-multiple-sclerosis-ms/